96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-004387-72-AT
(EUCTR)
11/10/200509/06/2005A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/AA Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A Crohn’s disease (CD) in patients with at least one perianal fistula.
MedDRA version: 7.1;Level: LLT;Classification code 10011401
Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody
Protein Design Labs, Inc.NULLNot RecruitingFemale: yes
Male: yes
18Phase 2aAustria;Germany
2EUCTR2004-004387-72-DE
(EUCTR)
03/06/200507/01/2005A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/AA Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease. - N/A Crohn’s disease (CD) in patients with at least one perianal fistula.
MedDRA version: 7.1;Level: LLT;Classification code 10011401
Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
18Phase 2aGermany
3EUCTR2004-004388-31-DE
(EUCTR)
03/06/200507/01/2005A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/AA Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease - N/A Moderate-to-severe inflammatory, nonstricturing, nonpenetrating Crohn’s disease (CD).
MedDRA version: 7.1;Level: LLT;Classification code 10011401
Product Name: Visilizumab
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: Anti-CD3 Monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
18Phase 2aGermany
4NCT00267709
(ClinicalTrials.gov)
February 200519/12/2005Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseA Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's DiseaseCrohn's DiseaseDrug: VisilizumabFacet BiotechPDL BioPharma, Inc.Completed18 Years70 YearsBoth18Phase 2United States
5NCT00267722
(ClinicalTrials.gov)
February 200519/12/2005Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseA Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's DiseaseCrohn's DiseaseDrug: VisilizumabFacet BiotechPDL BioPharma, Inc.Completed18 Years70 YearsBoth18Phase 2United States